Related Experiment Video

Updated: Aug 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

An Overview of Emerging Trends in Targeted Therapy of Triple-Negative Breast Cancer

Anuj Kumar1,2, Suresh Subramanian1

  • 1Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India, barc.ernet.in.

International Journal of Breast Cancer
|July 23, 2026
PubMed

Insights

Triple-negative breast cancer (TNBC) is an aggressive subtype affecting younger and minority women. New molecular targets and combination therapies show promise for improved TNBC management and patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking standard therapeutic targets (ER, PR, HER2).
  • TNBC disproportionately affects younger women and minority groups, presenting diagnostic and treatment challenges.
  • Current chemotherapy offers limited efficacy, leading to high relapse rates and reduced survival in TNBC patients.

Purpose of the Study:

  • To review the biological diversity and challenges in managing triple-negative breast cancer.
  • To highlight emerging molecular markers and therapeutic strategies for TNBC.
  • To emphasize the need for molecular subtype stratification in TNBC treatment.

Main Methods:

  • Review of current literature on TNBC biology, diagnosis, and treatment.
  • Analysis of novel molecular targets and therapeutic approaches in preclinical and clinical development.
  • Discussion of the role of the tumor microenvironment in TNBC metastasis.

Main Results:

  • TNBC exhibits significant molecular heterogeneity, influencing its aggressive behavior and treatment response.
  • Targeted therapies including antibody-drug conjugates (e.g., targeting Trop-2, Nectin-4) show promise.
  • Inhibitors of intracellular targets (e.g., PARP) and gene expression modulators are under investigation.
  • Tumor microenvironment composition impacts TNBC progression and metastasis.

Conclusions:

  • Molecular stratification of TNBC patients is crucial for personalized treatment.
  • Combining existing and novel therapeutic strategies is essential for effective TNBC management.
  • Further research into molecular subtypes and targeted therapies is needed to improve patient survival and outcomes.
Keywords:
TNBCantibody–drug complexbreast cancertargeted therapytriple-negative breast cancer

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...